Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

https://www.reuters.com/article/us-usa-healthcare-drugpricing-exclusive-idUSKBN1YZ1C4?utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=facebook&fbclid=IwAR3jZOVdv_tAkjjEd8ikoPUIqbCTKLAD9nhdmski_0miw5cI1EAC3mGCLdE

Michael Erman, Carl O'Donnell
December 31, 2019 / 4:00 PM

Drugmakers including Pfizer Inc (PFE.N), GlaxoSmithKline PLC (GSK.L) and Sanofi SA (SASY.PA) are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. The median price increase is around 5%, he said.

More price increases are expected to be announced later this week, which could affect the median and range.

•••••

Many branded drugmakers have pledged to keep their U.S. list price increases below 10% a year, under pressure from politicians and patients.

•••••